GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (LTS:0JW9) » Definitions » Cyclically Adjusted Book per Share

MEI Pharma (LTS:0JW9) Cyclically Adjusted Book per Share : $19.39 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is MEI Pharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

MEI Pharma's adjusted book value per share for the three months ended in Dec. 2024 was $3.317. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $19.39 for the trailing ten years ended in Dec. 2024.

During the past 12 months, MEI Pharma's average Cyclically Adjusted Book Growth Rate was -18.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -8.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -13.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -23.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of MEI Pharma was -7.40% per year. The lowest was -36.30% per year. And the median was -18.00% per year.

As of today (2025-05-13), MEI Pharma's current stock price is $2.0836. MEI Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was $19.39. MEI Pharma's Cyclically Adjusted PB Ratio of today is 0.11.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of MEI Pharma was 2.86. The lowest was 0.09. And the median was 0.43.


MEI Pharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for MEI Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Cyclically Adjusted Book per Share Chart

MEI Pharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.05 33.18 29.06 221.97 21.24

MEI Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.94 21.45 21.24 21.00 19.39

Competitive Comparison of MEI Pharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, MEI Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MEI Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MEI Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where MEI Pharma's Cyclically Adjusted PB Ratio falls into.


;
;

MEI Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MEI Pharma's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book= Book Value per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=3.317/133.1571*133.1571
=3.317

Current CPI (Dec. 2024) = 133.1571.

MEI Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201503 38.033 99.621 50.836
201506 35.006 100.684 46.296
201509 32.752 100.392 43.442
201512 30.233 99.792 40.341
201603 27.463 100.470 36.398
201606 24.386 101.688 31.933
201609 23.018 101.861 30.090
201612 29.848 101.863 39.018
201703 29.854 102.862 38.647
201706 27.644 103.349 35.617
201709 23.575 104.136 30.145
201712 20.700 104.011 26.501
201803 17.638 105.290 22.306
201806 14.335 106.317 17.954
201809 11.181 106.507 13.979
201812 15.032 105.998 18.884
201903 10.629 107.251 13.196
201906 13.035 108.070 16.061
201909 12.837 108.329 15.779
201912 14.582 108.420 17.909
202003 14.056 108.902 17.187
202006 13.820 108.767 16.919
202009 14.633 109.815 17.743
202012 13.064 109.897 15.829
202103 7.986 111.754 9.515
202106 8.785 114.631 10.205
202109 5.649 115.734 6.499
202112 11.625 117.630 13.160
202203 10.184 121.301 11.179
202206 7.872 125.017 8.385
202209 5.599 125.227 5.954
202212 7.260 125.222 7.720
202303 5.156 127.348 5.391
202306 3.696 128.729 3.823
202309 12.211 129.860 12.521
202312 8.928 129.419 9.186
202403 7.659 131.776 7.739
202406 4.956 132.554 4.979
202409 3.734 133.029 3.738
202412 3.317 133.157 3.317

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


MEI Pharma  (LTS:0JW9) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

MEI Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.0836/19.39
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of MEI Pharma was 2.86. The lowest was 0.09. And the median was 0.43.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


MEI Pharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


MEI Pharma Business Description

Industry
Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

MEI Pharma Headlines

No Headlines